Are you invested in Inflarx (IFRX)?
What’s up with Inflarx?
Inflarx (IFRX) opened at $6.93, which means the stock is up 4.55% from yesterday’s closing price of 6.82. Today, the company has a high of $7.30 and a low of $6.37. The company has a market cap of $186.13 million with a 52-week high of $45.72 and a 52-week low of $2.17.
What about the future for Inflarx?
The high forecast for Inflarx is 10.00 while the low is 3.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Inflarx has a weak forecast. A weak forecast is due to the company posting consistent losses in their earning reports. The future outlook does not seem too bright as this could potentially cause the company to file for bankruptcy.. Based on this information IFRX seems to be a risky buy.
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products include IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.